SCHEMBL3384994

SCHEMBL3384994

COc1ccc(C(=O)NCCc2c(C)[nH]c3ccccc23)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.68
ATM Q13315 1/20 0.64
POLB P06746 3/20 0.64
NPC1 O15118 2/20 0.64
RAB9A P51151 2/20 0.64
CDK4 P11802 1/20 0.60
CCND1 P24385 1/20 0.60
PABPC1 P11940 1/20 0.60
ALOX15 P16050 1/20 0.60
MTNR1A P48039 2/20 0.60
MTNR1B P49286 2/20 0.60
THRB P10828 1/20 0.59
TDP1 Q9NUW8 2/20 0.57
KMT2A Q03164 4/20 0.57
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605297 0.89 ATM (0.65) MAPTATMPOLBNPC1RAB9A
SCHEMBL3227065 0.88 MTNR1A (0.77) MAPTPOLBMTNR1AMTNR1BTDP1
SCHEMBL3230209 0.88 ATM (0.69) MAPTATMPOLBNPC1RAB9A
SCHEMBL7863760 0.88 MAPT (0.72) MAPTATMPOLBNPC1RAB9A
SCHEMBL3382735 0.88 ATM (0.63) MAPTATMPOLBNPC1RAB9A
SCHEMBL3384593 0.87 ATM (0.67) MAPTATMPOLBNPC1RAB9A
SCHEMBL3384743 0.86 MAPT (0.67) MAPTATMPOLBNPC1RAB9A
SCHEMBL3235845 0.86 ATM (0.66) MAPTATMPOLBNPC1RAB9A
SCHEMBL3230797 0.85 ATM (0.66) MAPTATMNPC1RAB9APABPC1
SCHEMBL3385026 0.85 ATM (0.65) MAPTATMNPC1RAB9ACDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor BAYER SCHERING PHARMA AG (DE) 2010-02-04 US claimed
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP claimed
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor BAYER SCHERING PHARMA AG (DE) 2010-02-04 US disclosed
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor PTGER2, PTGER1, PTGDR2 MAPT 4374/4885ATM 4060/4885POLB 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.